MagnetisMM-7: Enrolling for people with multiple myeloma

A clinical trial to assess a potential treatment option for multiple myeloma

The MagnetisMM-7 study is a phase 3 clinical trial enrolling around 700 participants with newly diagnosed multiple myeloma following autologous stem cell transplant (ASCT). The study is designed to assess whether the study medicine can provide clinical benefit when compared to the current standard of care therapy.

Who may participate

Participating in a clinical study is an important and personal decision. Thank you for considering the MagnetisMM-7 study.

This study may be an option for men and women who:

  • Are at least 18 years old
  • Have newly diagnosed multiple myeloma and have had an autologous (cells/tissue obtained from your body) stem-cell transplantation (ASCT)
  • Have not had previous maintenance treatment for multiple myeloma

There are other requirements for taking part in this study. We will explain these to you if you’d like to learn more.

If you’re interested in participating, you will review and sign an informed consent document and visit the study doctor’s office during a screening process to see whether you meet the eligibility criteria and are able to take part.

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enrol in the study.


Multiple myeloma 

Asset 22

The disease, disorder, syndrome, illness, or injury that is being studied.


18+ years 

Asset 22

The age a person must be to participate in a clinical trial.


Male or female

Asset 22

The sex of people who may participate in a clinical trial. Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.

What to expect

Length of study treatment

The total length of this study will vary depending on how long you receive the study medicines, but it could last up to seven years

Asset 22

Length of study treatment is the length of time the study participants will receive the study treatment.

Number of study visits

1-4 visits per 28-day cycle, until end of study treatment

Asset 22

Each clinical trial’s design specifies the number of study visits and the total length of the trial.

Long-term follow up

1 call or visit at least every 3 months 

Asset 22

Some studies require the study team to stay in contact with the participant for a period of time after the participant completes the main part of the study. This long-term follow up is to collect additional information on the study drug over time.

If you decide to take part in the study, you will be randomly (by chance) assigned to one of two treatment groups, called ‘Arms’. Each treatment group will receive the investigational medicine elranatamab or the comparator medicine lenalidomide.

Arm B

If assigned to Arm B, you will take the study comparator medicine lenalidomide as oral capsules every day and you will have one visit every one or two weeks for the first three months. After that, you will have one visit every four weeks.

Arm C

If assigned to Arm C, you will receive doses of the investigational medicine elranatamab as an injection under the skin every 2 weeks and you will visit the study doctor every 2 weeks. If you respond well to this regimen of the investigational medicine elranatamab for 6 months, you will then receive the full-dose of elranatamab every four weeks. Overnight hospitalization periods are required the first two times you receive the investigational medicine elranatamab.

The study team will perform tests and assessments throughout the study to monitor your health and safety as well as the effectiveness of the study medicines.


About a month after your last dose of the study medicine, there will be a final required visit. After this visit, you will have phone calls at least once every three months so the study team can check in on your health. Some additional follow-up visits may be required, depending on how your disease evolves.

Potential benefits and risks of taking part in the MagnetisMM-7 study

People who take part in clinical studies are key to advancing medical research. By taking part in the MagnetisMM-7 study, you will be aiding medical research which may help others with multiple myeloma in the future.

Over the course of the study, a participant’s health may get better, get worse, or stay the same. People who are considering taking part in the study will be given a complete list of risks and possible discomforts before agreeing to participate. As with any medication, there may be a reaction to the study medicine.

Frequently asked questions

Multiple myeloma is a type of blood cancer that forms in bone marrow. Healthy bone marrow produces plasma cells, which make antibodies to fight infection. But in multiple myeloma, plasma cells become cancerous. These cancer cells can crowd out normal blood cells, forming tumours and leaving a person vulnerable to infection.

The study drug is thought to work by connecting certain immune system cells, known as T-cells, to myeloma cells (cancer cells). Connecting these cells activates the immune cells, potentially killing the myeloma cells.

Informed consent is one of the most important tools to help you understand how your rights, safety, and well-being will be addressed throughout the trial.


During the informed consent discussion, you will be given all details about the study, including potential benefits and risks of taking part. You will also be given a document summarizing this information, which you will sign to confirm that you would like to take part in the clinical trial.

Yes, participation in clinical trials is completely voluntary: taking part in a trial is your choice. You are free to stop being in this trial at any time and for any reason and it will not affect your future medical care in any way.

Clinical trials are important to understand more about potential treatment options for all sorts of conditions. Clinical research studies also help us learn more about the side effects of a potential treatment and to understand whether the possible benefits outweigh the risks.

The study medicine and all study-related care and procedures are provided at no cost. You don’t need health insurance to join a clinical study. However, you (or your health insurance provider) may be responsible for medical expenses that are part of your usual healthcare. Talk with your study team or review the informed consent document to find out exactly what is covered.

Travel to the study centre and other expenses (such as meals) may be covered. Please discuss the details with your study team.

Find a clinical site near you

The MagnetisMM-7 study is taking place at research sites in multiple countries worldwide.

To find your nearest study site please enter your zip code and select the optimal distance to view on the map from the drop-down menu: